Free Content Activation-associated phenotype of CD3+ T cells in acute graft-versus-host disease

Authors: Paz Morante, M.1; Briones, J.2; Canto, E.1; Sabzevari, H.3; Martino, R.2; Sierra, J.2; Rodriguez-Sanchez, J. L.1; Vidal, S.

Source: Clinical & Experimental Immunology, Volume 145, Number 1, July 2006 , pp. 36-43(8)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Summary

During the effector phase of graft-versus-host disease (GvHD) response, donor T cells play an essential role and they are believed to change the expression of activation and co-stimulatory markers associated with functional alloreactivity. We analysed the expression of CD25, CD69, HLA-DR, CD154 and CD134 on CD4+ and CD8+ T cells by flow cytometry during acute GvHD (aGvHD) in 24 patients receiving human leucocyte antigen (HLA)-identical stem cell transplants. Expression of these molecules in nine patients with stages I-IV aGvHD was compared with 15 patients without aGvHD (n = 15). Serial analysis showed that peripheral blood of aGvHD patients presented a significant increase of CD4+ CD25+ cells (P < 0·03), CD4+ CD69+ (P < 0·04) and CD4+ CD134+ cells (P < 0·01). Additionally, there was a significant increase in CD8+ cells expressing CD134 (P = 0·007) and CD154 (P = 0·02). After resolution of aGvHD, the increased expression of these molecules returned to values comparable to patients without aGvHD. Only two of the 15 patients without clinical signs of aGvHD presented activated T cells that could not be attributed to development of aGvHD. In summary, our data show that multiple activation molecules are preferentially up-regulated on CD4+ and CD8+ T cells from patients with aGvHD. These patients had a significant increase in the expression of the co-stimulatory molecules CD134 and CD154.

Keywords: activation; CD4+ lymphocytes; CD8+ lymphocytes; GvHD; phenotype

Document Type: Research article

DOI: 10.1111/j.1365-2249.2006.03104.x

Affiliations: 1: Departments of Immunology, 2: Clinical Haematology and 3: Laboratory of Tumor Immunology and Biology, Hospital Sant Pau, Barcelona, Spain, and Center for Cancer Research, NCI, NIH, Bethesda-MD, USA

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A